Tweet
Aratana Therapeutics (NASDAQ:PETX) was upgraded by research analysts at ValuEngine from a "sell" rating to a "hold" rating in a report released on Wednesday.
A number of other equities research analysts also recently commented on PETX. Zacks Investment Research downgraded Aratana Therapeutics from a "buy" rating to a "hold" rating in a report on Wednesday. Stifel Nicolaus reduced their target price on Aratana Therapeutics from $8.00 to $7.00 and set a "buy" rating for the company in a report on Monday, August 6th. BidaskClub raised Aratana Therapeutics from a "hold" rating to a "buy" rating in a report on Thursday, May 10th. Finally, HC Wainwright set a $10.00 target price on Aratana Therapeutics and gave the company a "buy" rating in a report on Monday, May 7th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Aratana Therapeutics presently has a consensus rating of "Buy" and an average price target of $8.25. Get Aratana Therapeutics alerts:
Aratana Therapeutics stock opened at $5.25 on Wednesday. Aratana Therapeutics has a one year low of $3.67 and a one year high of $7.28. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.02 and a quick ratio of 2.44. The firm has a market capitalization of $244.79 million, a price-to-earnings ratio of -5.40 and a beta of 2.78. Aratana Therapeutics (NASDAQ:PETX) last released its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.05. Aratana Therapeutics had a negative return on equity of 35.25% and a negative net margin of 154.23%. The company had revenue of $4.91 million during the quarter, compared to the consensus estimate of $4.72 million. analysts predict that Aratana Therapeutics will post -0.48 earnings per share for the current year.
In other news, COO Brent Standridge sold 10,000 shares of the firm's stock in a transaction on Monday, June 25th. The stock was sold at an average price of $4.56, for a total value of $45,600.00. Following the completion of the transaction, the chief operating officer now owns 99,967 shares in the company, valued at $455,849.52. The sale was disclosed in a document filed with the SEC, which is available at this link . Also, insider Peter Steven St sold 11,513 shares of the firm's stock in a transaction on Monday, July 30th. The shares were sold at an average price of $4.33, for a total value of $49,851.29. Following the completion of the transaction, the insider now owns 649,233 shares of the company's stock, valued at approximately $2,811,178.89. The disclosure for this sale can be found here . In the last 90 days, insiders sold 39,187 shares of company stock valued at $186,472. Company insiders own 5.30% of the company's stock.
Several hedge funds have recently made changes to their positions in PETX. Geode Capital Management LLC increased its position in shares of Aratana Therapeutics by 7.4% in the fourth quarter. Geode Capital Management LLC now owns 313,626 shares of the biopharmaceutical company's stock valued at $1,649,000 after buying an additional 21,654 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Aratana Therapeutics by 55.6% in the fourth quarter. Renaissance Technologies LLC now owns 124,800 shares of the biopharmaceutical company's stock valued at $656,000 after buying an additional 44,600 shares in the last quarter. Deutsche Bank AG increased its position in shares of Aratana Therapeutics by 11.2% in the fourth quarter. Deutsche Bank AG now owns 468,114 shares of the biopharmaceutical company's stock valued at $2,461,000 after buying an additional 47,178 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Aratana Therapeutics by 35.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 68,039 shares of the biopharmaceutical company's stock valued at $358,000 after buying an additional 17,677 shares in the last quarter. Finally, Millennium Management LLC purchased a new position in shares of Aratana Therapeutics in the fourth quarter valued at $3,267,000. Institutional investors and hedge funds own 66.77% of the company's stock.
About Aratana Therapeutics
Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.
To view ValuEngine's full report, visit ValuEngine's official website . Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter 